HUGE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 13:13):

Stats
Today's Volume	86 167.00
Average Volume	149 709
Market Cap	19.22M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.030
ATR14	$0.00500 (1.05%)

Volume Correlation

Long: -0.13 (neutral)

Short: -0.68 (moderate negative)

Signal:(50.876) Neutral

FSD Pharma Inc Correlation

10 Most Positive Correlations
MDXG	0.944
MBIN	0.941
MIGI	0.933
TREE	0.932
SLMBP	0.929
SPPI	0.927
RKDA	0.925
HILS	0.924
KTCC	0.923
ICPT	0.922

10 Most Negative Correlations
ALHC	-0.922
XPDI	-0.914
ACRS	-0.914
GSMG	-0.911
GBNH	-0.911
DTSS	-0.907
CCSI	-0.898
JRJC	-0.896
ACHC	-0.895
EYE	-0.893

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

FSD Pharma Inc Correlation - Currency/Commodity

0.52
( weak )

0.47
( neutral )

0.00
( neutral )

-0.02
( neutral )

FSD Pharma Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-2.55M (0.00 %)
EPS:	$-0.470

Q4	2023
Revenue:	$0
Gross Profit:	$-125 594 (0.00 %)
EPS:	$-0.0431

Q3	2023
Revenue:	$0
Gross Profit:	$-144 945 (0.00 %)
EPS:	$-0.0289

Q2	2023
Revenue:	$0
Gross Profit:	$-1.12M (0.00 %)
EPS:	$-0.210

Financial Reports:

No articles found.

FSD Pharma Inc

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.